Description: Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control™ platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology and expects to file an IND for its first program later this year.
Home Page: foghorntx.com
FHTX Technical Analysis
500 Technology Square
Cambridge,
MA
02139
United States
Phone:
617 586 3100
Officers
| Name | Title |
|---|---|
| Mr. Adrian H. B. Gottschalk | Pres, CEO & Director |
| Dr. Allan Reine M.D. | Chief Financial Officer |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Dr. Gerald R. Crabtree M.d. | Founder & Member of Scientific Advisory Board |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer |
| Mr. Ben Strain | VP of Investor Relations & Corp. Communications |
| Mr. Michael J. LaCascia | Chief Legal Officer |
| Mr. Saurabh Sewak Ph.D. | VP of Corp. Devel. |
| Mr. Carlos Costa | Chief People Officer |
| Ms. Fanny Cavalie | Chief Strategy & Bus. Operations Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.707 |
| Price-to-Sales TTM: | 17.0317 |
| IPO Date: | 2020-10-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 119 |